Biopharma Daily Updates - 12/17/20

XBI: $146.65 (+1.47%)

Covid:

$MRNA (+5%) - FDA ADCOM vote in favor of emergency use

https://investors.modernatx.com/news-releases/news-release-details/moderna-receives-fda-advisory-committee-vote-supporting

Pipeline:

$ZYNE (-16.5%) - After FDA meeting, conducting phase 3 for Zygel in FXS

https://ir.zynerba.com/news-releases/news-release-details/zynerba-pharmaceuticals-provides-regulatory-update-zygeltm

$RVNC (+5.8%) - Positive results from phase 2 upper facial lines study

https://investors.revance.com/news-releases/news-release-details/revance-reports-positive-efficacy-and-duration-results-phase-2

$ALBO (-1.4%) - Global ph3 initiation & NDA submission

https://ir.albireopharma.com/news-releases/news-release-details/albireo-initiates-global-phase-3-clinical-trial-odevixibat

$MNKD (+1.25%) - Co-promote Thyquidity w/ Vertice Pharma

https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-and-vertice-co-promote-thyquiditytm-levothyroxine

Financial:

$GMDA (+4.2%) - Prices offering at $8/share